FANCI is a negative regulator of Akt activation

References

• Porta C, Paglino C, Mosca A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol 2014; 4:64; PMID:24782981; http://dx.doi.org/10.3389/fonc.2014.00064
   PubMedGoogle Scholar
• Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, Cuenca-Lopez MD, Seruga B, Pandiella A, Amir E. Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis. PLoS One 2014; 9:e95219; PMID:24777052; http://dx.doi.org/10.1371/journal.pone.0095219
   PubMed Web of Science ®Google Scholar
• Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13:140-56; PMID:24481312; http://dx.doi.org/10.1038/nrd4204
   PubMed Web of Science ®Google Scholar
• Stebbing J, Lit LC, Zhang H, Darrington RS, Melaiu O, Rudraraju B, Giamas G. The regulatory roles of phosphatases in cancer. Oncogene 2014; 33:939-53; PMID:23503460; http://dx.doi.org/10.1038/onc.2013.80
   PubMed Web of Science ®Google Scholar
• Fayard E, Xue G, Parcellier A, Bozulic L, Hemmings BA. Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. Curr Topics Microbiol Immunol 2010; 346:31-56; PMID:20517722
   PubMed Web of Science ®Google Scholar
• Dummler B, Hemmings BA. Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans 2007; 35:231-5; PMID:17371246; http://dx.doi.org/10.1042/BST0350231
   PubMed Web of Science ®Google Scholar
• Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 1996; 15:6541-51; PMID:8978681
   PubMed Web of Science ®Google Scholar
• Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, McCormick F, Feng J, Tsichlis P. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998; 17:313-25; PMID:9690513; http://dx.doi.org/10.1038/sj.onc.1201947
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-101; PMID:15718470; http://dx.doi.org/10.1126/science.1106148
   PubMed Web of Science ®Google Scholar
• Bayascas JR, Alessi DR. Regulation of Akt/PKB Ser473 phosphorylation. Mol Cell 2005; 18:143-5; PMID:15837416; http://dx.doi.org/10.1016/j.molcel.2005.03.020
   PubMed Web of Science ®Google Scholar
• Bozulic L, Surucu B, Hynx D, Hemmings BA. PKBalpha/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival. Mol Cell 2008; 30:203-13; PMID:18439899; http://dx.doi.org/10.1016/j.molcel.2008.02.024
   PubMed Web of Science ®Google Scholar
• Boehme KA, Kulikov R, Blattner C. p53 stabilization in response to DNA damage requires Akt/PKB and DNA-PK. Proc Natl Acad Sci U S A 2008; 105:7785-90; PMID:18505846; http://dx.doi.org/10.1073/pnas.0703423105
   PubMed Web of Science ®Google Scholar
• Liu P, Begley M, Michowski W, Inuzuka H, Ginzberg M, Gao D, Tsou P, Gan W, Papa A, Kim BM, et al. Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature 2014; 508:541-5; PMID:24670654; http://dx.doi.org/10.1038/nature13079
   PubMed Web of Science ®Google Scholar
• Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005; 18:13-24; PMID:15808505; http://dx.doi.org/10.1016/j.molcel.2005.03.008
   PubMed Web of Science ®Google Scholar
• Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 2007; 25:917-31; PMID:17386267; http://dx.doi.org/10.1016/j.molcel.2007.02.017
   PubMed Web of Science ®Google Scholar
• O'Neill AK, Niederst MJ, Newton AC. Suppression of survival signalling pathways by the phosphatase PHLPP. Febs J 2013; 280:572-83; PMID:22340730; http://dx.doi.org/10.1111/j.1742-4658.2012.08537.x
   PubMed Web of Science ®Google Scholar
• Gao T, Brognard J, Newton AC. The phosphatase PHLPP controls the cellular levels of protein kinase C. J Biol Chem 2008; 283:6300-11; PMID:18162466; http://dx.doi.org/10.1074/jbc.M707319200
   PubMed Web of Science ®Google Scholar
• Liu J, Stevens PD, Li X, Schmidt MD, Gao T. PHLPP-mediated dephosphorylation of S6K1 inhibits protein translation and cell growth. Mol Cell Biol 2011; 31:4917-27; PMID:21986499; http://dx.doi.org/10.1128/MCB.05799-11
   PubMed Web of Science ®Google Scholar
• Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W, Stein J, Stein GS, Iglehart JD, Shi Q, et al. Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 2010; 38:512-23; PMID:20513427; http://dx.doi.org/10.1016/j.molcel.2010.03.017
   PubMed Web of Science ®Google Scholar
• Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009; 16:259-66; PMID:19732725; http://dx.doi.org/10.1016/j.ccr.2009.07.016
   PubMed Web of Science ®Google Scholar
• Li X, Yang H, Liu J, Schmidt MD, Gao T. Scribble-mediated membrane targeting of PHLPP1 is required for its negative regulation of Akt. EMBO Rep 2011; 12:818-24; PMID:21701506; http://dx.doi.org/10.1038/embor.2011.106
   PubMed Web of Science ®Google Scholar
• Molina JR, Agarwal NK, Morales FC, Hayashi Y, Aldape KD, Cote G, Georgescu MM. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene 2012; 31:1264-74; PMID:21804599; http://dx.doi.org/10.1038/onc.2011.324
   PubMed Web of Science ®Google Scholar
• Wang P, Zhou Z, Hu A, Ponte de Albuquerque C, Zhou Y, Hong L, Sierecki E, Ajiro M, Kruhlak M, Harris C, et al. Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Mol Cell 2014; 54:378-91; PMID:24703948; http://dx.doi.org/10.1016/j.molcel.2014.03.007
   PubMed Web of Science ®Google Scholar
• Chen M, Pratt CP, Zeeman ME, Schultz N, Taylor BS, O'Neill A, Castillo-Martin M, Nowak DG, Naguib A, Grace DM, et al. Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. Cancer Cell 2011; 20:173-86; PMID:21840483; http://dx.doi.org/10.1016/j.ccr.2011.07.013
   PubMed Web of Science ®Google Scholar
• Hellwinkel OJ, Rogmann JP, Asong LE, Luebke AM, Eichelberg C, Ahyai S, Isbarn H, Graefen M, Huland H, Schlomm T. A comprehensive analysis of transcript signatures of the phosphatidylinositol-3 kinase/protein kinase B signal-transduction pathway in prostate cancer. BJU Int 2008; 101:1454-60; PMID:18336616; http://dx.doi.org/10.1111/j.1464-410X.2008.07540.x
   PubMed Web of Science ®Google Scholar
• Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18:11-22; PMID:20579941; http://dx.doi.org/10.1016/j.ccr.2010.05.026
   PubMed Web of Science ®Google Scholar
• Kupfer GM. Fanconi anemia: a signal transduction and DNA repair pathway. Yale J Biol Med 2013; 86:491-7; PMID:24348213
   PubMedGoogle Scholar
• Sakaguchi H, Nakanishi K, Kojima S. Inherited bone marrow failure syndromes in 2012. Int J Hematol 2013; 97:20-9; PMID:23271412; http://dx.doi.org/10.1007/s12185-012-1249-9
   PubMed Web of Science ®Google Scholar
• Shukla P, Solanki A, Ghosh K, Vundinti BR. DNA interstrand cross-link repair: understanding role of Fanconi anemia pathway and therapeutic implications. Eur J Haematol 2013; 91:381-93; PMID:23859405; http://dx.doi.org/10.1111/ejh.12169
   PubMed Web of Science ®Google Scholar
• Dong H, Nebert DW, Bruford EA, Thompson DC, Joenje H, Vasiliou V. Update of the human and mouse Fanconi anemia genes. Hum Genomics 2015; 9:32; PMID:26596371; http://dx.doi.org/10.1186/s40246-015-0054-y
   PubMed Web of Science ®Google Scholar
• Panneerselvam J, Pickering A, Han B, Li L, Zheng J, Zhang J, Zhang Y, Fei P. Basal level of FANCD2 monoubiquitination is required for the maintenance of a sufficient number of licensed-replication origins to fire at a normal rate. Oncotarget 2014; 5:1326-37; PMID:24658369; http://dx.doi.org/10.18632/oncotarget.1796
   PubMed Web of Science ®Google Scholar
• Berquist BR, Wilson DM, 3rd. Pathways for repairing and tolerating the spectrum of oxidative DNA lesions. Cancer Lett 2012; 327:61-72; PMID:22353689; http://dx.doi.org/10.1016/j.canlet.2012.02.001
   PubMed Web of Science ®Google Scholar
• Crossan GP, Patel KJ. The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA. J Pathol 2012; 226:326-37; PMID:21956823; http://dx.doi.org/10.1002/path.3002
   PubMed Web of Science ®Google Scholar
• Clark DW, Tripathi K, Dorsman JC, Palle K. FANCJ protein is important for the stability of FANCD2/FANCI proteins and protects them from proteasome and caspase-3 dependent degradation. Oncotarget 2015; 6:28816-32; PMID:26336824
   PubMed Web of Science ®Google Scholar
• Meetei AR, de Winter JP, Medhurst AL, Wallisch M, Waisfisz Q, van de Vrugt HJ, Oostra AB, Yan Z, Ling C, Bishop CE, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet 2003; 35:165-70; PMID:12973351; http://dx.doi.org/10.1038/ng1241
   PubMed Web of Science ®Google Scholar
• Gregory RC, Taniguchi T, D'Andrea AD. Regulation of the Fanconi anemia pathway by monoubiquitination. Semin Cancer Biol 2003; 13:77-82; PMID:12507559; http://dx.doi.org/10.1016/S1044-579X(02)00102-5
   PubMed Web of Science ®Google Scholar
• Smogorzewska A, Matsuoka S, Vinciguerra P, McDonald ER, 3rd, Hurov KE, Luo J, Ballif BA, Gygi SP, Hofmann K, D'Andrea AD, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell 2007; 129:289-301; PMID:17412408; http://dx.doi.org/10.1016/j.cell.2007.03.009
   PubMed Web of Science ®Google Scholar
• Sims AE, Spiteri E, Sims RJ, 3rd, Arita AG, Lach FP, Landers T, Wurm M, Freund M, Neveling K, Hanenberg H, et al. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol 2007; 14:564-7; PMID:17460694; http://dx.doi.org/10.1038/nsmb1252
   PubMed Web of Science ®Google Scholar
• Kim H, D'Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev 2012; 26:1393-408; PMID:22751496; http://dx.doi.org/10.1101/gad.195248.112
   PubMed Web of Science ®Google Scholar
• Panneerselvam J, Pickering A, Zhang J, Wang H, Tian H, Zheng J, Fei P. A hidden role of the inactivated FANCD2: upregulating DeltaNp63. Oncotarget 2013; 4:1416-26; PMID:23965832; http://dx.doi.org/10.18632/oncotarget.1217
   PubMed Web of Science ®Google Scholar
• Park E, Kim H, Kim JM, Primack B, Vidal-Cardenas S, Xu Y, Price BD, Mills AA, D'Andrea AD. FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. Mol Cell 2013; 50:908-18; PMID:23806336; http://dx.doi.org/10.1016/j.molcel.2013.05.017
   PubMed Web of Science ®Google Scholar
• Cohn MA, Kowal P, Yang K, Haas W, Huang TT, Gygi SP, D'Andrea AD. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol Cell 2007; 28:786-97; PMID:18082604; http://dx.doi.org/10.1016/j.molcel.2007.09.031
   PubMed Web of Science ®Google Scholar
• Nijman SM, Huang TT, Dirac AM, Brummelkamp TR, Kerkhoven RM, D'Andrea AD, Bernards R. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 2005; 17:331-9; PMID:15694335; http://dx.doi.org/10.1016/j.molcel.2005.01.008
   PubMed Web of Science ®Google Scholar
• Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009; 138:389-403; PMID:19615732; http://dx.doi.org/10.1016/j.cell.2009.04.042
   PubMed Web of Science ®Google Scholar
• Ishiai M, Kitao H, Smogorzewska A, Tomida J, Kinomura A, Uchida E, Saberi A, Kinoshita E, Kinoshita-Kikuta E, Koike T, et al. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol 2008; 15:1138-46; PMID:18931676; http://dx.doi.org/10.1038/nsmb.1504
   PubMed Web of Science ®Google Scholar
• Dragoi AM, Fu X, Ivanov S, Zhang P, Sheng L, Wu D, Li GC, Chu WM. DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA. EMBO J 2005; 24:779-89; PMID:15678105; http://dx.doi.org/10.1038/sj.emboj.7600539
   PubMed Web of Science ®Google Scholar
• Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 2004; 279:41189-96; PMID:15262962; http://dx.doi.org/10.1074/jbc.M406731200
   PubMed Web of Science ®Google Scholar
• Huang TT, Nijman SM, Mirchandani KD, Galardy PJ, Cohn MA, Haas W, Gygi SP, Ploegh HL, Bernards R, D'Andrea AD. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol 2006; 8:339-47; PMID:16531995
   PubMed Web of Science ®Google Scholar
• Agarwal NK, Zhu X, Gagea M, White CL, 3rd, Cote G, Georgescu MM. PHLPP2 suppresses the NF-kappaB pathway by inactivating IKKbeta kinase. Oncotarget 2014; 5:815-23; PMID:24553260; http://dx.doi.org/10.18632/oncotarget.1774
   PubMed Web of Science ®Google Scholar
• Dorsman JC, Levitus M, Rockx D, Rooimans MA, Oostra AB, Haitjema A, Bakker ST, Steltenpool J, Schuler D, Mohan S, et al. Identification of the Fanconi anemia complementation group I gene, FANCI. Cell Oncol 2007; 29:211-8; PMID:17452773
   PubMed Web of Science ®Google Scholar
• Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9:1956-67; PMID:20571069; http://dx.doi.org/10.1158/1535-7163.MCT-09-1012
   PubMed Web of Science ®Google Scholar
• Ameziane N, Sie D, Dentro S, Ariyurek Y, Kerkhoven L, Joenje H, Dorsman JC, Ylstra B, Gille JJ, Sistermans EA, et al. Diagnosis of fanconi anemia: mutation analysis by next-generation sequencing. Anemia 2012; 2012:132856; PMID:22720145; http://dx.doi.org/10.1155/2012/132856
   PubMedGoogle Scholar
• Patil AA, Sayal P, Depondt ML, Beveridge RD, Roylance A, Kriplani DH, Myers KN, Cox A, Jellinek D, Fernando M, et al. FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents. Oncotarget 2014; 5:6414-24; PMID:25071006; http://dx.doi.org/10.18632/oncotarget.2225
   PubMed Web of Science ®Google Scholar
• Shen C, Houghton PJ. Targeting FANCD2 for therapy sensitization. Oncotarget 2014; 5:3426-7; PMID:24913333; http://dx.doi.org/10.18632/oncotarget.2070
   PubMed Web of Science ®Google Scholar
• Cheng YC, Chen PH, Chiang HY, Suen CS, Hwang MJ, Lin TY, Yang HC, Lin WC, Lai PL, Shieh SY. Candidate tumor suppressor B-cell translocation gene 3 impedes neoplastic progression by suppression of AKT. Cell Death Dis 2015; 6:e1584; http://dx.doi.org/10.1038/cddis.2014.550
   Google Scholar
• Geng L, Zhang X, Zheng S, Legerski RJ. Artemis links ATM to G2/M checkpoint recovery via regulation of Cdk1-cyclin B. Mol Cell Biol 2007; 27:2625-35; PMID:17242184; http://dx.doi.org/10.1128/MCB.02072-06
   PubMed Web of Science ®Google Scholar
• Huang Y, Leung JW, Lowery M, Matsushita N, Wang Y, Shen X, Huong D, Takata M, Chen J, Li L. Modularized functions of the Fanconi anemia core complex. Cell Rep 2014; 7:1849-57; PMID:24910428; http://dx.doi.org/10.1016/j.celrep.2014.04.029
   PubMed Web of Science ®Google Scholar
• Ahkter S, Richie CT, Zhang N, Behringer RR, Zhu C, Legerski RJ. Snm1-deficient mice exhibit accelerated tumorigenesis and susceptibility to infection. Mol Cell Biol 2005; 25:10071-8; PMID:16260620; http://dx.doi.org/10.1128/MCB.25.22.10071-10078.2005
   PubMed Web of Science ®Google Scholar